Krishnaswami Vijayaraghavan
Cardiovascular Disease · Scottsdale, AZNPI 1376598151
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $753,278 of the $927,310 with a category attached, or 81.2%. 37 manufacturers reported payments, led by Novo Nordisk at 25.0% of the total. Reporting peaked in 2019 at $215,089 and has fallen 91.3% since, to $18,719 in 2025. Among cardiovascular disease clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 865 payments — averaging $1072.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$232K
- Boehringer Ingelheim$115K
- AstraZeneca$103K
- Lilly USA, LLC$102K
- Amarin Pharma, Inc.$79K
- Lexicon Pharmaceuticals, Inc.$75K
- plus $222K from 31 others
What the payments were for
- Consulting fees$86,0569%
- Speaking & faculty fees$753,27881%
- Travel & lodging$67,8397%
- Food & beverage$20,1112%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 138 | $231,626 |
| Boehringer Ingelheim | 122 | $114,609 |
| AstraZeneca | 130 | $102,777 |
| Lilly USA, LLC | 80 | $101,713 |
| Amarin Pharma, Inc. | 74 | $78,679 |
| Lexicon Pharmaceuticals, Inc. | 71 | $75,428 |
| Pfizer | 50 | $56,819 |
| Kiniksa Pharmaceuticals International, PLC | 35 | $31,693 |
| Eli Lilly | 11 | $30,600 |
| Kiniksa Pharmaceuticals, Ltd. | 20 | $21,788 |
| Amgen | 28 | $19,670 |
| Scpharmaceuticals Inc. | 6 | $15,567 |
| Esperion Therapeutics, Inc. | 11 | $13,056 |
| Novartis | 15 | $8,706 |
| Baxter Healthcare | 6 | $5,027 |
| BD | 1 | $4,950 |
| Edwards Lifesciences | 6 | $4,714 |
| Bayer | 3 | $3,026 |
| E.r. Squibb & Sons, L.L.C. | 2 | $2,055 |
| Medtronic(2 entities) | 13 | $1,950 |
| Amryt Pharma Holdings Ltd | 1 | $640 |
| Vifor Pharma, Inc. | 7 | $392 |
| Merck | 4 | $323 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $248 |
| Sanofi-aventis U.S. LLC | 3 | $196 |
| Boston Scientific | 2 | $179 |
| Regeneron Healthcare Solutions, Inc. | 3 | $134 |
| Alnylam Pharmaceuticals Inc. | 2 | $127 |
| Kowa Pharmaceuticals America, Inc. | 1 | $122 |
| Valeritas, Inc. | 1 | $106 |
| Kaneka Medical America LLC | 1 | $104 |
| Abiomed | 1 | $95 |
| Regeneron | 1 | $87 |
| Abbott | 3 | $63 |
| Akcea Therapeutics, Inc. | 1 | $29 |
| Sensible Medical Innovations Inc | 1 | $7 |
| Travere Therapeutics, Inc. | 6 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$927,310 in reported general payments places this provider in the 95th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Scottsdale
- Paul UnderwoodScottsdale$259K
- Robert BurkeScottsdale$207K
- David RizikScottsdale$128K
- Martin CerdaScottsdale$66K
- Pattara RattanawongScottsdale$43K
- Mayank SardanaScottsdale$36K
- Ashish GuptaPhoenix$1.1M
- Rajkumar SugumaranPhoenix$957K
- Steven MottlTucson$340K
- Omar WaniFlagstaff$244K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.